Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. More Details
Flawless balance sheet with poor track record.
Share Price & News
How has Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1349 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1349's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1349 underperformed the Hong Kong Pharmaceuticals industry which returned 8.4% over the past year.
Return vs Market: 1349 underperformed the Hong Kong Market which returned 21.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Shares?
1 month ago | Simply Wall StDid Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Share Price Deserve to Gain 27%?
2 months ago | Simply Wall StWhat To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1349 (HK$5.15) is trading above our estimate of fair value (HK$1.39)
Significantly Below Fair Value: 1349 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1349 is poor value based on its PE Ratio (23.3x) compared to the Hong Kong Pharmaceuticals industry average (13.4x).
PE vs Market: 1349 is poor value based on its PE Ratio (23.3x) compared to the Hong Kong market (11.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1349's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1349 is overvalued based on its PB Ratio (2.2x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Fudan-Zhangjiang Bio-Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Shanghai Fudan-Zhangjiang Bio-Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1349 has a high level of non-cash earnings.
Growing Profit Margin: 1349's current net profit margins (20.3%) are lower than last year (20.8%).
Past Earnings Growth Analysis
Earnings Trend: 1349's earnings have grown by 10.3% per year over the past 5 years.
Accelerating Growth: 1349's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1349 had negative earnings growth (-7.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.2%).
Return on Equity
High ROE: 1349's Return on Equity (9.3%) is considered low.
How is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 1349's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥338.1M).
Long Term Liabilities: 1349's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥58.7M).
Debt to Equity History and Analysis
Debt Level: 1349 is debt free.
Reducing Debt: 1349 has no debt compared to 5 years ago when its debt to equity ratio was 11.5%.
Debt Coverage: 1349 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1349 has no debt, therefore coverage of interest payments is not a concern.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1349's dividend (1.17%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.9%).
High Dividend: 1349's dividend (1.17%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.06%).
Stability and Growth of Payments
Stable Dividend: 1349 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1349 has only been paying a dividend for 6 years, and since then payments have not increased.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27.2%), 1349's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hai Bo Wang (61 yo)
Mr. Haibo Bo Wang co-founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. in November 1996 and serves as its Chairman of the Board and General Manager. Mr. Wang serves as Chairman of the Board and...
CEO Compensation Analysis
Compensation vs Market: Hai Bo's total compensation ($USD507.66K) is about average for companies of similar size in the Hong Kong market ($USD647.16K).
Compensation vs Earnings: Hai Bo's compensation has been consistent with company performance over the past year.
Experienced Management: 1349's management team is seasoned and experienced (15.4 years average tenure).
Experienced Board: 1349's board of directors are considered experienced (7.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Ticker: 1349
- Exchange: SEHK
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$17.456b
- Shares outstanding: 1.04b
- Website: https://www.fd-zj.com
Number of Employees
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Zhangjiang Hi-Tech Park
- No. 308 Cailun Road
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform dru...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/21 16:33|
|End of Day Share Price||2021/06/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.